Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | POLG | P54098 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | FBP1 | P09467 | 2/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.43 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21518153 | 0.79 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL29641197 | 0.79 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL21518150 | 0.79 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL5083599 | 0.79 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL5086376 | 0.77 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL5082287 | 0.77 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL28343435 | 0.76 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADORA1 | |
| SCHEMBL5086069 | 0.75 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL5086075 | 0.75 | CYP3A4 (0.46) | PI4KAPI4K2BPI4K2API4KBSLC22A6 | |
| SCHEMBL28484184 | 0.75 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892511-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Lauren Sciences LLC (US) | 2015-07-15 | — | — | EP | claimed |
| WO-2014039502-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2014-03-13 | — | — | WO | claimed |
| WO-2021209563-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-10-21 | — | — | WO | disclosed |
| EP-3463469-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS | Gilead Sciences, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3288589-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | Foresight Biotherapeutics, Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017205078-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTIONS USING NS5A, NS5B OR NS3 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2016176396-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | FORESIGHT BIOTHERAPEUTICS, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| EP-3033087-A2 | COMPOSITIONS AND METHODS FOR IDENTIFYING LATENTLY INFECTED CELLS | The J. David Gladstone Institutes (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2981334-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY | The Regents of the University of California (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2968228-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | Quadex Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2892511-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Lauren Sciences LLC (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2013059426-A1 | HUMAN ENDOGENOUS RETROVIRUS PEPTIDES, ANTIBODIES TO THE PEPTIDES, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-2547792-A1 | PHARMACOGENOMIC AND RESPONSE-GUIDED TREATMENT OF INFECTIOUS DISEASE USING YEAST-BASED IMMUNOTHERAPY | Globeimmune, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2012174220-A1 | YEAST-BASED COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF HEPATITIS DELTA VIRUS INFECTION | GLOBEIMMUNE, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012109404-A1 | YEAST-BASED THERAPEUTIC FOR CHRONIC HEPATITIS B INFECTION | GLOBEIMMUNE, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012047852-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNODEFICIENCY VIRUS TRANSCRIPTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011115914-A1 | PHARMACOGENOMIC AND RESPONSE-GUIDED TREATMENT OF INFECTIOUS DISEASE USING YEAST-BASED IMMUNOTHERAPY | GLOBEIMMUNE, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2244782-A2 | LINEAR ORDER RELEASE POLYMER | The University of Utah Research Foundation (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094573-A9 | LINEAR ORDER RELEASE POLYMER | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009094573-A2 | LINEAR ORDER RELEASE POLYMER | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-07-30 | — | — | WO | disclosed |